Summary: A new study identifies dopamine dysfunction as an overlooked cause of memory loss in Alzheimer’s disease. By examining the entorhinal cortex—the brain’s gateway to the hippocampus and a key hub for memory processing—researchers found dopamine levels drop to under 20% of normal in an Alzheimer’s mouse model, causing memory-encoding circuits to fail.
Importantly, the team restored dopamine signaling either with optogenetic stimulation or with the Parkinson’s medication Levodopa (L‑DOPA). Both approaches normalized neural activity and fully reversed cognitive deficits in the animals, pointing to a promising new direction for therapies aimed at restoring memory.
Key Facts
- The entorhinal collapse: In a knock‑in mouse model of Alzheimer’s, dopamine in the entorhinal cortex fell to less than 20% of baseline, causing memory‑encoding neurons to stop responding to stimuli.
- Associative memory failure: This dramatic dopamine loss was linked to pronounced deficits in associative memory, demonstrated by the animals’ inability to complete odor‑based learning tasks.
- Beyond plaques and tangles: Unlike therapies focused on removing amyloid‑β or tau pathology, this work targets the active circuitry required for memories to form and be retrieved.
- Two independent rescue methods: Memory and neural activity were rescued both by targeted optogenetic reactivation of dopamine fibers and by systemic administration of Levodopa (L‑DOPA), a drug commonly used in Parkinson’s disease.
Source: Tohoku University
Imagine if lost memories could be restored. What once sounded like science fiction may be closer to reality: researchers at Tohoku University, with collaborators at the University of California, Irvine, report that early dopamine disruption in the entorhinal cortex drives memory impairment in Alzheimer’s models and that restoring dopamine signaling can reverse those deficits.
The full findings were published in Nature Neuroscience on April 23, 2026.
Everyday memory often ties to sensory cues: a scent that transports you back to childhood, or a song that triggers a vivid recollection. Neuroscientists have long identified the medial temporal lobe—and the hippocampus and its inputs—as central to forming these memories. Still, the specific circuit disruptions that cause memory loss in Alzheimer’s disease have remained unclear.
Led by Kei Igarashi at Tohoku University School of Medicine, the research team focused on the entorhinal cortex, the major gateway to the hippocampus. Prior work suggested dopamine plays a key role in memory encoding in this region; the current study asked whether dopamine dysfunction contributes to Alzheimer’s‑related memory loss.
Using an amyloid precursor protein knock‑in mouse model, the researchers measured dopamine levels in the lateral entorhinal cortex (LEC). They observed a severe reduction in dopamine—below 20% of normal—which coincided with striking impairments on associative memory tasks, particularly odor‑based learning. Electrophysiological recordings showed LEC neurons failed to respond to events that would normally be encoded as memories.
To test causality, the team used optogenetics to selectively reactivate dopamine fibers projecting to the LEC. This targeted stimulation restored proper neural responses and rescued associative learning. In parallel, systemic administration of L‑DOPA also reinstated normal neural activity and improved behavioral memory performance in the same model.
“We found that dopamine dysfunction is a central driver of memory impairment in Alzheimer’s disease,” said Kei Igarashi. “The result was unexpected but it opens new therapeutic possibilities for millions affected by this condition.”
Current therapeutics that aim to clear amyloid‑β or modulate tau have had limited impact on reversing cognitive decline. This study shifts attention to the functional state of memory circuits themselves and suggests therapies that restore dopamine signaling in the entorhinal cortex could directly reboot memory encoding mechanisms rather than only attempting to remove pathological proteins.
Dopamine‑based interventions therefore represent a promising avenue for future clinical research in Alzheimer’s disease. While these findings come from animal models and require careful translation to humans, they provide a compelling rationale to investigate entorhinal dopamine as a therapeutic target.
Key Questions Answered:
A: Parkinson’s disease involves dopamine loss in motor circuits, so Levodopa replenishes dopamine to restore function. This study shows a parallel in memory circuits: Alzheimer’s pathology can severely deplete dopamine in the entorhinal cortex. Replenishing dopamine with L‑DOPA refuels those starved circuits, normalizing neural responses and restoring memory behavior in the animal model.
A: The entorhinal cortex acts as the main entry point to the hippocampus, routing sensory and contextual information into the memory system. If entorhinal neurons lack sufficient dopamine, they fail to fire appropriately, effectively blocking experiences from being encoded as lasting memories.
A: Not yet. The experiments were performed in a mouse model, so translation to human patients requires clinical testing. However, the findings represent a major conceptual advance: they show that targeting neurotransmitter signaling in specific memory circuits may restore function even when traditional pathology‑focused approaches have limited benefit.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by editorial staff.
About this Alzheimer’s disease and neuropharmacology research news
Author: Public Relations Office
Source: Tohoku University
Contact: Public Relations Office – Tohoku University
Image: Image credited to Neuroscience News
Original Research: Open access. “Early dopamine disruption in the entorhinal cortex of a knock‑in model of Alzheimer’s disease” by Tatsuki Nakagawa et al., Nature Neuroscience. DOI: 10.1038/s41593-026-02260-w
Abstract
Early dopamine disruption in the entorhinal cortex of a knock‑in model of Alzheimer’s disease
The entorhinal cortex is critical for memory formation and exhibits some of the earliest functional and histological changes in Alzheimer’s disease. Although this region has long been implicated as an originating site of disease pathology, the circuit mechanisms underlying its selective vulnerability have been unclear.
This study demonstrates that dopamine neurons projecting to the lateral entorhinal cortex (LEC), which support memory formation in healthy brains, become dysfunctional at an early pathological stage in an amyloid precursor protein knock‑in mouse model. Dopamine loss disrupted associative memory encoding in LEC layer 2/3. Optogenetic reactivation of LEC dopamine fibers rescued associative learning behavior, and systemic L‑DOPA treatment restored LEC neural encoding and associative memory in the model. These results indicate that early dysfunction of LEC‑projecting dopamine neurons contributes to memory impairment in Alzheimer’s disease and support clinical investigation of entorhinal dopamine in patients with AD.